Taysha Gene Therapies (TSHA) FCF Margin (2023 - 2025)
Taysha Gene Therapies' (TSHA) quarterly FCF Margin came in at 2263.61% in Q4 2025, down 137449.0% year-on-year from N/an in Q4 2024, and down 122.39% quarter-over-quarter from 1017.88% in Q2 2025.
Taysha Gene Therapies (TSHA) FCF Margin (2023 - 2025) Analysis & Trends
Taysha Gene Therapies has disclosed FCF Margin across 3 years of filings, most recently posting 2263.61% for Q4 2025.
- FCF Margin for Q4 2025 came in at 2263.61%, down 137449.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 3512.57% (down 235350.0% YoY), and the FY2025 annual result was 1705.96%, down 73067.0% from the prior year.
- FCF Margin came in at 2263.61% for Q4 2025 at Taysha Gene Therapies, down from 1017.88% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 305.94% in Q3 2023 to a low of 2263.61% in Q4 2025.
- The 3-year median for FCF Margin is 889.12% (2024), against an average of 1003.32%.
- Peak annual rise in FCF Margin reached 94337 bps in 2025, while the deepest fall reached 137449 bps in 2025.
- Taysha Gene Therapies' FCF Margin stood at 542.81% in 2023, then slumped by 64 bps to 889.12% in 2024, then slumped by 155 bps to 2263.61% in 2025.
- The last three FCF Margin figures came in at 2263.61% (Q4 2025), 1017.88% (Q2 2025), and 972.98% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Taysha Gene Therapies | 2.36 Bn | 2.36 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,263.61% |
| Jun 30, 2025 | -1,017.88% |
| Mar 31, 2025 | -972.98% |
| Dec 31, 2024 | -889.12% |
| Sep 30, 2024 | -1,205.03% |
| Jun 30, 2024 | -1,961.24% |
| Mar 31, 2024 | -584.52% |
| Dec 31, 2023 | -542.81% |
| Sep 30, 2023 | -305.94% |
| Jun 30, 2023 | -781.59% |
| Mar 31, 2023 | -511.79% |